Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Non Regulatory May 18, 2022Invitation to presentation of Vivesto’s Q1 report 2022 on May 25
-
Regulatory April 29, 2022New number of shares and votes in Vivesto
-
Regulatory April 28, 2022Correction: Vivesto publishes Annual Report for 2021
Vivesto will publish its Q1 report for 2022 on May 25, 2022, at 08.00 am CET. The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English and followed by a question-and-answer session.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program
Did you know that #WorldOvarianCancerDay is on May 8? We are proud to be developing new treatments that we hope may make a difference to patients. Learn more about ovarian cancer and check out its symptoms here:
#WOCD2022 #NoWomanLeftBehind
Home
The World Ovarian Cancer Coalition
worldovariancancercoalition.org
Today, we signed a research agreement with Visikol Inc., a leading U.S. #CRO, to evaluate the cellular effects of anti-cancer drug formulations developed using our proprietary XR-17™ and XR-18 technologies.
#oncology #biotech
Vivesto signs agreement with leading US CRO to evaluate anti-cancer drug formulations using its proprietary drug delivery platforms - Vivesto
Solna, Sweden, 19 April 2022 – Vivesto AB, an oncology-focused specialty pharmaceutical company, today announces that ...
bit.ly
